Cybin (NASDAQ:HELP) Shares Up 9.7% Following Insider Buying Activity

Cybin Inc. (NASDAQ:HELP) traded up 9.7% during mid-day trading on Monday after an insider bought additional shares in the company. The company traded as high as $13.38 and last traded at $13.5660. 487,342 shares changed hands during mid-day trading, a decline of 61% from the average daily volume of 1,235,494 shares. The stock had previously closed at $12.37.

Specifically, CEO Michael Halstead bought 100,000 shares of the business’s stock in a transaction on Monday, September 21st. The shares were bought at an average price of $13.47 per share, with a total value of $1,347,000.00. Following the completion of the transaction, the chief executive officer directly owned 168,568 shares in the company, valued at $2,270,610.96. This trade represents a 145.84% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Analyst Upgrades and Downgrades

HELP has been the subject of a number of research reports. Wall Street Zen raised Cybin from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 29th. Wells Fargo & Company initiated coverage on Cybin in a report on Monday, July 27th. They set an “overweight” rating and a $16.00 target price for the company. Barclays assumed coverage on Cybin in a research report on Friday, September 18th. They issued an “overweight” rating and a $35.00 target price for the company. Finally, TD Cowen boosted their price target on shares of Cybin from $8.00 to $62.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Six research analysts have rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $46.33.

Cybin News Summary

Here are the key news stories impacting Cybin this week:

• Positive Sentiment: CEO Michael Halstead purchased 100,000 shares at an average price of $13.47, investing approximately $1.35 million. The transaction increased his direct holdings by about 146% and may be interpreted as a strong vote of confidence in the company’s outlook. SEC insider transaction filing
• Positive Sentiment: Cybin presented four new analyses of HLP003, its investigational oral deuterated psilocin analog, at Psych Congress 2026. The analyses further characterized the drug and its Phase 3 PARADIGM program for adjunctive treatment of major depressive disorder, potentially increasing investor confidence in the development pipeline. HLP003 Psych Congress announcement
• Positive Sentiment: Shareholders overwhelmingly approved the appointment of Zeifmans LLP as auditor, an eight-member board and all director nominees. Strong approval of the resolutions supports management’s governance plans as the company advances its clinical programs. Annual and special meeting results
• Positive Sentiment: The company will legally change its name from Cybin Inc. to Helus Pharma Inc. on October 1, reflecting its goal of transitioning from a discovery and development company into a commercial-ready pharmaceutical business. Management is also scheduled to discuss its serotonergic pipeline at the TD Cowen Neuropsychiatry Summit on September 23. TD Cowen summit announcement
• Neutral Sentiment: Analyst price targets remain widely dispersed, with recent targets ranging from $8 to $70. The bullish targets could improve sentiment, but the wide range highlights substantial uncertainty about clinical and commercial execution.
• Negative Sentiment: HLP003 and the broader serotonergic pipeline remain investigational. Regulatory approval, successful Phase 3 results and commercialization are not guaranteed, and the company continues to face development costs and potential losses.

Cybin Price Performance

The firm has a 50 day moving average price of $10.95 and a 200-day moving average price of $7.17. The firm has a market capitalization of $1.08 billion, a price-to-earnings ratio of -4.54 and a beta of 0.63.

Cybin (NASDAQ:HELP) last released its earnings results on Friday, August 14th. The company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). Equities research analysts predict that Cybin Inc. will post -2.95 earnings per share for the current year.

Institutional Investors Weigh In On Cybin

A hedge fund recently bought a new stake in Cybin stock. AXQ Capital LP purchased a new position in shares of Cybin Inc. (NASDAQ:HELP) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 11,315 shares of the company’s stock, valued at approximately $75,000. 17.94% of the stock is currently owned by hedge funds and other institutional investors.

Cybin Company Profile

Cybin Inc is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for the treatment of mental health conditions. The company combines drug discovery, clinical development and proprietary formulation technologies to design potentially more efficient and scalable psychedelic treatments.

Cybin’s development programs have included CYB003, an investigational deuterated psilocybin analog being studied for major depressive disorder, and CYB004, an investigational deuterated DMT molecule being evaluated for generalized anxiety disorder and other mental health indications.